國航(00753.HK)11月客運力投入按年跌26.2%
中國國航(00753.HK)公布,11月份客運運力投入按年跌26.2%,按月跌11.3%;旅客周轉量按年跌22.7%,按月跌14.2%。其中,內地客運運力投入按年跌32.1%,按月跌14.1%;旅客周轉量按年跌27.3%,按月跌16.2%;平均客座率為62.1%,按年升2.8個百分點,按月跌2.1個百分點。
月內,貨運運力投入按年跌57.5%,按月跌29.7%;貨郵周轉量按年跌56.9%,按月跌28.4%;貨運載運率為44.1%,按年升0.6個百分點,按月升0.8個百分點。
截至今年11月底,集團合計營運757架飛機,其中自有飛機306架,融資租賃247架,經營租賃204架。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.